CRAB’s Clinical Research Services (CRS) division provides our private biopharmaceutical clients with expert consulting, experienced clinical development support, and full-service clinical trial service offerings. Built upon decades of experience in cancer research, our CRS division is focused on delivering customized clinical trial strategies that assure reliable answers to research questions.
Two new partners enhance our service offerings.
Our collaboration with IGC will offer clients reliable biomarker assays which will be incorporated with the research data base. The IGC is a non-profit, medical research organization specializing in human tissue biobanking, molecular analysis and the translational development of diagnostic and theranostic testing.
CRAB and Imaging Endpoints are working in collaboration to streamline
the transferring, storage and analysis of clinical trial imaging data from
participating clinical sites for centralized image review required in many
clinical trials. Together the team will seek to integrate imaging with clinical
data and other metrics to define unique image features for biomarker
discovery and surrogate endpoints through a consolidated database which seamlessly connects
imaging with patient outcome data.
As a nimble and efficient niche provider, we are the ideal partner for smaller and emerging biopharmaceutical companies who want to partner with a scientifically-oriented, oncology-focused provider. CRAB’s CRS division can provide either full-service support, or functional service offerings that are aligned with our client’s outsourcing strategy. We pride ourselves on our ability to be flexible, client-centric, and focused on helping our clients achieve their development goals.